NeuroMetrix, Inc. Logo

NeuroMetrix, Inc.

NURO

(1.2)
Stock Price

3,82 USD

-25.49% ROA

-30.66% ROE

-5.18x PER

Market Cap.

3.543.936,00 USD

1.36% DER

0% Yield

-108.34% NPM

NeuroMetrix, Inc. Stock Analysis

NeuroMetrix, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NeuroMetrix, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.22x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

5 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

6 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

8 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

9 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

10 ROE

Negative ROE (-25.04%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

11 ROA

The stock's ROA (-25.49%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

NeuroMetrix, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NeuroMetrix, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

NeuroMetrix, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NeuroMetrix, Inc. Revenue
Year Revenue Growth
2001 3.464.379
2002 4.225.007 18%
2003 9.167.557 53.91%
2004 17.920.089 48.84%
2005 34.298.133 47.75%
2006 55.249.716 37.92%
2007 44.622.211 -23.82%
2008 31.120.800 -43.38%
2009 26.137.026 -19.07%
2010 13.899.670 -88.04%
2011 10.396.775 -33.69%
2012 7.575.289 -37.25%
2013 5.278.806 -43.5%
2014 5.512.764 4.24%
2015 7.299.830 24.48%
2016 12.027.528 39.31%
2017 17.092.336 29.63%
2018 16.090.138 -6.23%
2019 9.272.522 -73.52%
2020 7.377.975 -25.68%
2021 8.253.493 10.61%
2022 8.256.073 0.03%
2023 4.812.656 -71.55%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NeuroMetrix, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2001 2.560.961
2002 2.146.060 -19.33%
2003 2.396.772 10.46%
2004 3.268.363 26.67%
2005 3.820.624 14.45%
2006 5.010.513 23.75%
2007 4.891.937 -2.42%
2008 5.256.721 6.94%
2009 5.611.296 6.32%
2010 5.855.353 4.17%
2011 3.877.526 -51.01%
2012 3.545.790 -9.36%
2013 3.438.218 -3.13%
2014 4.075.976 15.65%
2015 3.894.786 -4.65%
2016 4.394.353 11.37%
2017 3.497.636 -25.64%
2018 5.134.592 31.88%
2019 3.101.976 -65.53%
2020 2.391.316 -29.72%
2021 2.596.415 7.9%
2022 3.239.725 19.86%
2023 2.370.616 -36.66%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NeuroMetrix, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 4.844.378.000 100%
2005 7.332.783.000 33.94%
2006 11.805.062.000 37.88%
2007 14.834.073.000 20.42%
2008 12.016.158 -123351.05%
2009 9.119.001 -31.77%
2010 7.231.875 -26.09%
2011 5.111.616 -41.48%
2012 4.735.238 -7.95%
2013 4.225.474 -12.06%
2014 4.725.123 10.57%
2015 5.497.513 14.05%
2016 4.872.670 -12.82%
2017 5.689.917 14.36%
2018 4.841.278 -17.53%
2019 5.923.190 18.27%
2020 3.516.340 -68.45%
2021 3.990.141 11.87%
2022 4.386.666 9.04%
2023 4.824.924 9.08%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NeuroMetrix, Inc. EBITDA
Year EBITDA Growth
2001 -520.869
2002 -4.572.388 88.61%
2003 -3.339.260 -36.93%
2004 -3.329.002 -0.31%
2005 855.141 489.29%
2006 3.427.223 75.05%
2007 -9.748.310 135.16%
2008 5.256.819 285.44%
2009 -1.215.425 532.51%
2010 -16.786.183 92.76%
2011 -9.626.095 -74.38%
2012 -10.022.027 3.95%
2013 -6.692.878 -49.74%
2014 -9.769.270 31.49%
2015 -17.359.792 43.72%
2016 -15.483.607 -12.12%
2017 -13.291.098 -16.5%
2018 -12.291.567 -8.13%
2019 -11.534.711 -6.56%
2020 -2.094.904 -450.61%
2021 -2.284.607 8.3%
2022 -4.741.766 51.82%
2023 -7.843.592 39.55%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NeuroMetrix, Inc. Gross Profit
Year Gross Profit Growth
2001 2.040.092
2002 2.854.848 28.54%
2003 6.461.018 55.81%
2004 13.066.763 50.55%
2005 25.440.039 48.64%
2006 41.691.662 38.98%
2007 32.560.413 -28.04%
2008 22.108.859 -47.27%
2009 18.601.410 -18.86%
2010 6.849.461 -171.57%
2011 5.674.706 -20.7%
2012 3.986.483 -42.35%
2013 3.084.547 -29.24%
2014 2.944.162 -4.77%
2015 3.349.084 12.09%
2016 4.914.523 31.85%
2017 6.856.798 28.33%
2018 7.383.056 7.13%
2019 2.245.623 -228.78%
2020 5.249.558 57.22%
2021 5.921.660 11.35%
2022 5.750.240 -2.98%
2023 3.127.128 -83.88%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NeuroMetrix, Inc. Net Profit
Year Net Profit Growth
2001 -8.717.494
2002 -4.793.463 -81.86%
2003 -3.666.708 -30.73%
2004 -4.283.989 14.41%
2005 938.258 556.59%
2006 4.267.806 78.02%
2007 -8.378.474 150.94%
2008 -27.730.049 69.79%
2009 -11.917.500 -132.68%
2010 -16.891.148 29.45%
2011 -9.981.105 -69.23%
2012 -10.007.553 0.26%
2013 -8.019.137 -24.8%
2014 -7.766.222 -3.26%
2015 -9.187.348 15.47%
2016 -14.913.151 38.39%
2017 -12.859.253 -15.97%
2018 23.605 54576.82%
2019 -3.649.002 100.65%
2020 -2.002.241 -82.25%
2021 -2.205.079 9.2%
2022 -4.367.218 49.51%
2023 -7.074.948 38.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NeuroMetrix, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 -8.683
2002 -4.774 -81.86%
2003 -3.652 -30.72%
2004 -4.103 10.99%
2005 230 1883.91%
2006 3.917 94.13%
2007 -7.645 151.23%
2008 -23.263 67.14%
2009 -8.185 -184.22%
2010 -8.454 3.18%
2011 -4.973 -70%
2012 -1.496 -232.64%
2013 -432 -246.87%
2014 -305 -41.78%
2015 -182 -67.96%
2016 -178 -1.69%
2017 -76 -137.33%
2018 0 0%
2019 -4 100%
2020 -1 0%
2021 0 0%
2022 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NeuroMetrix, Inc. Free Cashflow
Year Free Cashflow Growth
2002 -4.589.902
2003 -4.076.983 -12.58%
2004 -3.196.789 -27.53%
2005 1.432.966 323.09%
2006 6.677.363 78.54%
2007 -8.246.635 180.97%
2008 -11.218.335 26.49%
2009 -6.829.202 -64.27%
2010 -13.613.565 49.84%
2011 -6.889.385 -97.6%
2012 -9.283.032 25.79%
2013 -6.640.987 -39.78%
2014 -7.905.801 16%
2015 -13.694.459 42.27%
2016 -15.180.775 9.79%
2017 -12.815.480 -18.46%
2018 2.718.130 571.48%
2019 -3.669.329 174.08%
2020 -2.066.861 -77.53%
2021 -2.205.404 6.28%
2022 -5.312.598 58.49%
2023 -2.200.057 -141.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NeuroMetrix, Inc. Operating Cashflow
Year Operating Cashflow Growth
2002 -4.559.980
2003 -3.873.372 -17.73%
2004 -2.651.631 -46.08%
2005 1.908.090 238.97%
2006 7.297.903 73.85%
2007 -7.989.115 191.35%
2008 -10.688.463 25.25%
2009 -6.137.087 -74.16%
2010 -13.307.114 53.88%
2011 -6.778.398 -96.32%
2012 -9.175.567 26.13%
2013 -6.554.908 -39.98%
2014 -7.678.493 14.63%
2015 -13.099.853 41.38%
2016 -15.080.276 13.13%
2017 -12.652.384 -19.19%
2018 2.861.713 542.13%
2019 -3.621.253 179.03%
2020 -2.066.861 -75.21%
2021 -2.073.694 0.33%
2022 -5.289.416 60.8%
2023 -2.061.881 -156.53%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NeuroMetrix, Inc. Capital Expenditure
Year Capital Expenditure Growth
2002 29.922
2003 203.611 85.3%
2004 545.158 62.65%
2005 475.124 -14.74%
2006 620.540 23.43%
2007 257.520 -140.97%
2008 529.872 51.4%
2009 692.115 23.44%
2010 306.451 -125.85%
2011 110.987 -176.11%
2012 107.465 -3.28%
2013 86.079 -24.84%
2014 227.308 62.13%
2015 594.606 61.77%
2016 100.499 -491.65%
2017 163.096 38.38%
2018 143.583 -13.59%
2019 48.076 -198.66%
2020 0 0%
2021 131.710 100%
2022 23.182 -468.16%
2023 138.176 83.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NeuroMetrix, Inc. Equity
Year Equity Growth
2002 -39.928.491
2003 -45.502.320 12.25%
2004 34.056.318 233.61%
2005 36.248.063 6.05%
2006 43.408.586 16.5%
2007 46.729.871 7.11%
2008 22.832.551 -104.66%
2009 35.709.871 36.06%
2010 20.198.972 -76.79%
2011 11.088.521 -82.16%
2012 8.800.422 -26%
2013 7.194.975 -22.31%
2014 3.387.115 -112.42%
2015 12.562.708 73.04%
2016 4.960.764 -153.24%
2017 5.017.389 1.13%
2018 6.097.811 17.72%
2019 2.530.234 -141%
2020 5.247.775 51.78%
2021 23.215.786 77.4%
2022 23.355.687 0.6%
2023 19.903.536 -17.34%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NeuroMetrix, Inc. Assets
Year Assets Growth
2002 7.053.006
2003 7.217.781 2.28%
2004 37.952.528 80.98%
2005 42.897.071 11.53%
2006 55.706.279 22.99%
2007 56.374.574 1.19%
2008 31.378.342 -79.66%
2009 40.566.520 22.65%
2010 23.066.429 -75.87%
2011 14.220.783 -62.2%
2012 10.877.447 -30.74%
2013 10.796.763 -0.75%
2014 11.402.230 5.31%
2015 16.034.490 28.89%
2016 8.283.891 -93.56%
2017 9.599.224 13.7%
2018 12.113.248 20.75%
2019 6.893.686 -75.72%
2020 7.994.575 13.77%
2021 24.888.192 67.88%
2022 24.669.615 -0.89%
2023 21.286.772 -15.89%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NeuroMetrix, Inc. Liabilities
Year Liabilities Growth
2002 46.981.497
2003 52.720.101 10.89%
2004 3.896.210 -1253.11%
2005 6.649.008 41.4%
2006 12.297.693 45.93%
2007 9.644.703 -27.51%
2008 8.545.791 -12.86%
2009 4.856.649 -75.96%
2010 2.867.457 -69.37%
2011 3.132.262 8.45%
2012 2.077.025 -50.81%
2013 3.601.788 42.33%
2014 8.015.115 55.06%
2015 3.471.782 -130.86%
2016 3.323.127 -4.47%
2017 4.581.835 27.47%
2018 6.015.437 23.83%
2019 4.363.452 -37.86%
2020 2.746.800 -58.86%
2021 1.672.406 -64.24%
2022 1.313.928 -27.28%
2023 1.383.236 5.01%

NeuroMetrix, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.75
Net Income per Share
-0.64
Price to Earning Ratio
-5.18x
Price To Sales Ratio
0.55x
POCF Ratio
-4.6
PFCF Ratio
-0.57
Price to Book Ratio
1.41
EV to Sales
0.34
EV Over EBITDA
-0.36
EV to Operating CashFlow
-0.36
EV to FreeCashFlow
-0.35
Earnings Yield
-0.19
FreeCashFlow Yield
-1.77
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
5.79
Graham NetNet
2.06

Income Statement Metrics

Net Income per Share
-0.64
Income Quality
1.1
ROE
-0.25
Return On Assets
-0.3
Return On Capital Employed
-0.35
Net Income per EBT
0.98
EBT Per Ebit
0.91
Ebit per Revenue
-1.21
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
0.74
Research & Developement to Revenue
0.4
Stock Based Compensation to Revenue
0.11
Gross Profit Margin
0.67
Operating Profit Margin
-1.21
Pretax Profit Margin
-1.11
Net Profit Margin
-1.08

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.72
Free CashFlow per Share
-0.74
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.02
Capex to Depreciation
-3.68
Return on Invested Capital
-0.29
Return on Tangible Assets
-0.25
Days Sales Outstanding
34.87
Days Payables Outstanding
39.16
Days of Inventory on Hand
289.46
Receivables Turnover
10.47
Payables Turnover
9.32
Inventory Turnover
1.26
Capex per Share
-0.02

Balance Sheet

Cash per Share
2,07
Book Value per Share
2,34
Tangible Book Value per Share
2.34
Shareholders Equity per Share
2.34
Interest Debt per Share
-0
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.22
Current Ratio
16.43
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.01
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1625297
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NeuroMetrix, Inc. Dividends
Year Dividends Growth
2007 0

NeuroMetrix, Inc. Profile

About NeuroMetrix, Inc.

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

CEO
Dr. Shai N. Gozani M.D., Ph.D.
Employee
26
Address
4B Gill Street
Woburn, 01801

NeuroMetrix, Inc. Executives & BODs

NeuroMetrix, Inc. Executives & BODs
# Name Age
1 Mr. Thomas T. Higgins
Senior Vice President, Chief Financial Officer & Treasurer
70
2 Dr. Xuan Kong Ph.D.
Chief Data Scientist
70
3 Dr. Shai N. Gozani M.D., Ph.D.
Founder, Chairman, Chief Executive Officer, President & Secretary
70
4 Ms. Susan M. Bell R.N.
Senior Vice President of Population Health & Value Based Care
70

NeuroMetrix, Inc. Competitors